The U.S. Department of Health and Human Services (HHS) is re-evaluating its stance on fluoride in drinking water by reconvening the Community Preventive Services Task Force, an independent panel of health experts. This move follows Health Secretary Robert F. Kennedy Jr.’s recent statement in Salt Lake City, indicating plans to halt the Centers for Disease Control and Prevention’s recommendation for community water fluoridation.
Fluoride, commonly added to public water supplies to prevent tooth decay, has been a controversial topic for decades. While the American Dental Association continues to support fluoridation as an effective dental health measure, concerns about potential health risks have gained traction.
The Environmental Protection Agency (EPA) will also review new scientific data on fluoride’s health effects. EPA Administrator Lee Zeldin confirmed that this effort is in collaboration with HHS, with the goal of re-evaluating the agency’s current enforceable fluoride limit of 4.0 milligrams per liter (mg/L). Currently, the U.S. Public Health Service recommends maintaining levels below 0.7 mg/L. Studies show that exposure above 1.5 mg/L can increase risks of bone fractures, thyroid dysfunction, and neurological damage.
In a landmark move, Utah became the first state to ban fluoride in public water systems after Governor Spencer Cox signed new legislation last month. The decision faced strong opposition from health experts and organizations, including the American Dental Association.
As of 2022, about 63% of Americans receive fluoridated water through their municipal systems. A 2024 federal court ruling ordered the EPA to tighten its standards, citing unacceptable health risks to children under current fluoride levels. While Kennedy claims links between fluoride and conditions like cancer, his statements remain unsubstantiated by definitive scientific evidence.


Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
Ukraine-Russia Talks Yield Major POW Swap as U.S. Pushes for Path to Peace
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Iran–U.S. Nuclear Talks in Oman Face Major Hurdles Amid Rising Regional Tensions
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding
UAE Plans Temporary Housing Complex for Displaced Palestinians in Southern Gaza
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Marco Rubio Steps Down as Acting U.S. Archivist Amid Federal Law Limits
U.S. to Begin Paying UN Dues as Financial Crisis Spurs Push for Reforms
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business 



